Computational design and discovery of "minimally structured" hERG blockers.

Molecular knowledge of hERG blocking liability can offer the possibility of optimizing lead compounds in a way that eliminates potentially lethal side effects. In this study, we computationally designed, synthesized, and tested a small series of "minimally structured" molecules. Some of these compounds were remarkably potent against hERG (6, IC(50) = 2.4 nM), allowing us to identify the minimal structural requirements for hERG blocking liability.

[1]  Andreas Bender,et al.  Prospective Validation of a Comprehensive In silico hERG Model and its Applications to Commercial Compound and Drug Databases , 2010, ChemMedChem.

[2]  J. Valentin,et al.  An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.

[3]  Maurizio Recanatini,et al.  hERG-related drug toxicity and models for predicting hERG liability and QT prolongation , 2009, Expert opinion on drug metabolism & toxicology.

[4]  Jürgen Bajorath,et al.  Combining Cluster Analysis, Feature Selection and Multiple Support Vector Machine Models for the Identification of Human Ether‐a‐go‐go Related Gene Channel Blocking Compounds , 2009, Chemical biology & drug design.

[5]  Andrea Cavalli,et al.  Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies , 2008, J. Comput. Chem..

[6]  Matteo Masetti,et al.  Modeling hERG and its Interactions with Drugs: Recent Advances in Light of Current Potassium Channel Simulations , 2008, ChemMedChem.

[7]  G. Ecker,et al.  A binary QSAR model for classification of hERG potassium channel blockers. , 2008, Bioorganic & medicinal chemistry.

[8]  M. Sutcliffe,et al.  Drug block of the hERG potassium channel: Insight from modeling , 2007, Proteins.

[9]  Steffen Hering,et al.  State-dependent dissociation of HERG channel inhibitors , 2007, British journal of pharmacology.

[10]  N. Standen,et al.  Modulation of hERG potassium currents in HEK‐293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits , 2007, The Journal of physiology.

[11]  Scott Boyer,et al.  Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data , 2007, J. Comput. Aided Mol. Des..

[12]  G. Scuseria,et al.  Gaussian 03, Revision E.01. , 2007 .

[13]  A. Aronov.  Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. , 2006, Journal of medicinal chemistry.

[14]  R. Shah,et al.  Can pharmacogenetics help rescue drugs withdrawn from the market? , 2006, Pharmacogenomics.

[15]  J. Hancox,et al.  Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656 , 2006, FEBS letters.

[16]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[17]  Raymond L Woosley,et al.  Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs , 2006, Journal of Pharmacology and Experimental Therapeutics.

[18]  Michael J Sutcliffe,et al.  Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs , 2006, Molecular Pharmacology.

[19]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[20]  Nicole Schmitt,et al.  Local Anesthetic Interaction with Human Ether-a-go-go–related Gene (HERG) Channels: Role of Aromatic Amino Acids Y652 and F656 , 2005, Anesthesiology.

[21]  F. Österberg,et al.  Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods , 2005, FEBS letters.

[22]  Sonja Claassen,et al.  Comparison of the Effects of Metoclopramide and Domperidone on HERG Channels , 2005, Pharmacology.

[23]  P. Tarantino,et al.  Effect of trazodone on hERG channel current and QT-interval. , 2005, European journal of pharmacology.

[24]  Ki-Suk Kim,et al.  The Phenothiazine Drugs Inhibit hERG Potassium Channels , 2005, Drug and chemical toxicology.

[25]  菊池 幹.  Blockade of HERG cardiac K[+] current by antifungal drug miconazole , 2005 .

[26]  Chris Pollard,et al.  Comparative Pharmacology of Guinea Pig Cardiac Myocyte and Cloned hERG (IKr) Channel , 2004, Journal of cardiovascular electrophysiology.

[27]  Hugo A. Katus,et al.  Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[28]  H. Katus,et al.  Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[29]  B. Wible,et al.  Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action , 2004, British Journal of Pharmacology.

[30]  Jules C Hancox,et al.  Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation. , 2004, Biochemical and biophysical research communications.

[31]  Brian B. Goldman,et al.  A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.

[32]  J. Hancox,et al.  Lidoflazine is a high affinity blocker of the HERG K(+)channel. , 2004, Journal of molecular and cellular cardiology.

[33]  Gregory W. Kauffman,et al.  Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.

[34]  Martin Traebert,et al.  Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. , 2004, European journal of pharmacology.

[35]  G. Gintant,et al.  Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. , 2004, Journal of molecular and cellular cardiology.

[36]  M. Hiraoka,et al.  Effects of Na+ Channel Blocker, Pilsicainide, on HERG Current Expressed in HEK‐293 Cells , 2003, Journal of cardiovascular pharmacology.

[37]  Roy J. Vaz,et al.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.

[38]  Hao Wang,et al.  Functional and pharmacological properties of canine ERG potassium channels. , 2003, American journal of physiology. Heart and circulatory physiology.

[39]  J. Tamargo,et al.  Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block , 2002, British journal of pharmacology.

[40]  C. January,et al.  The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels. , 2002, Cardiovascular research.

[41]  Jiesheng Kang,et al.  A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. , 2002, European journal of pharmacology.

[42]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[43]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[44]  Jules C Hancox,et al.  Inhibitory actions of the selective serotonin re‐uptake inhibitor citalopram on HERG and ventricular L‐type calcium currents , 2002, FEBS letters.

[45]  Jiesheng Kang,et al.  Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. , 2001, The Journal of pharmacology and experimental therapeutics.

[46]  W. Crumb,et al.  Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. , 2001, The Journal of pharmacology and experimental therapeutics.

[47]  O. Pongs,et al.  Screening lead compounds for QT interval prolongation. , 2001, Drug discovery today.

[48]  D J Triggle,et al.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.

[49]  L. Annunziato,et al.  Inhibition of HERG1 K+ channels by the novel second‐generation antihistamine mizolastine , 2000, British journal of pharmacology.

[50]  C R Benedict,et al.  Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. , 2000, The Journal of pharmacology and experimental therapeutics.

[51]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  O. Pongs,et al.  Effects of fluoroquinolones on HERG currents. , 2000, European journal of pharmacology.

[53]  B. Drolet,et al.  Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders , 2000, Circulation.

[54]  T J Campbell,et al.  Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. , 2000, Cardiovascular research.

[55]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[56]  W. Crumb,et al.  Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. , 2000, The Journal of pharmacology and experimental therapeutics.

[57]  C. January,et al.  Droperidol Lengthens Cardiac Repolarization due to Block of the Rapid Component of the Delayed Rectifier Potassium Current , 1999, Journal of cardiovascular electrophysiology.

[58]  C. January,et al.  Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.

[59]  C. January,et al.  Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. , 1998, Molecular pharmacology.

[60]  W. C. Still,et al.  The GB/SA Continuum Model for Solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii , 1997 .

[61]  B Attali,et al.  The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes , 1997, British journal of pharmacology.

[62]  David A. Fletcher,et al.  The United Kingdom Chemical Database Service , 1996, J. Chem. Inf. Comput. Sci..

[63]  F. Lang,et al.  Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole , 1996, FEBS letters.

[64]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[65]  Thomas A. Halgren,et al.  Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular. interactions , 1996, J. Comput. Chem..

[66]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[67]  P. Kollman,et al.  Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation , 1993 .

[68]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[69]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[70]  G. Chang,et al.  An internal-coordinate Monte Carlo method for searching conformational space , 1989 .

[71]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[72]  L. Wise,et al.  1-[3-(Diarylamino)propyl]piperidines and related compounds, potential antipsychotic agents with low cataleptogenic profiles. , 1985, Journal of Medicinal Chemistry.

[73]  J. Tilley,et al.  Antagonists of slow-reacting substance of anaphylaxis. 1. Pyrido[2,1-b]quinazolinecarboxylic acid derivatives. , 1983, Journal of medicinal chemistry.

[74]  Bruce R. Kowalski,et al.  Partial least-squares path modelling with latent variables , 1979 .